Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke

Sverre E. Kjeldsen, Paulette A. Lyle, Jorge Kizer, Suzanne Oparil, Aud Høieggen, Ingrid Os

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.

Original languageEnglish (US)
Pages (from-to)299-305
Number of pages7
JournalVascular Health and Risk Management
Volume3
Issue number3
StatePublished - 2007
Externally publishedYes

Fingerprint

Risk Reduction Behavior
Losartan
Stroke
Hydrochlorothiazide
Therapeutics
Hypertension
Angiotensin Type 1 Receptor
Atenolol
Patient Compliance
Renin-Angiotensin System
Antihypertensive Agents
losartan drug combination hydrochlorothiazide
Diabetes Mellitus
Blood Pressure

Keywords

  • Angiotensin receptor blocker
  • Combination therapy
  • Hydrochlorothiazide
  • Hypertension
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

Kjeldsen, S. E., Lyle, P. A., Kizer, J., Oparil, S., Høieggen, A., & Os, I. (2007). Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. Vascular Health and Risk Management, 3(3), 299-305.

Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. / Kjeldsen, Sverre E.; Lyle, Paulette A.; Kizer, Jorge; Oparil, Suzanne; Høieggen, Aud; Os, Ingrid.

In: Vascular Health and Risk Management, Vol. 3, No. 3, 2007, p. 299-305.

Research output: Contribution to journalArticle

Kjeldsen, SE, Lyle, PA, Kizer, J, Oparil, S, Høieggen, A & Os, I 2007, 'Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke', Vascular Health and Risk Management, vol. 3, no. 3, pp. 299-305.
Kjeldsen SE, Lyle PA, Kizer J, Oparil S, Høieggen A, Os I. Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. Vascular Health and Risk Management. 2007;3(3):299-305.
Kjeldsen, Sverre E. ; Lyle, Paulette A. ; Kizer, Jorge ; Oparil, Suzanne ; Høieggen, Aud ; Os, Ingrid. / Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. In: Vascular Health and Risk Management. 2007 ; Vol. 3, No. 3. pp. 299-305.
@article{4405314a984747678d441852fb5dd68b,
title = "Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke",
abstract = "A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25{\%} risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.",
keywords = "Angiotensin receptor blocker, Combination therapy, Hydrochlorothiazide, Hypertension, Stroke",
author = "Kjeldsen, {Sverre E.} and Lyle, {Paulette A.} and Jorge Kizer and Suzanne Oparil and Aud H{\o}ieggen and Ingrid Os",
year = "2007",
language = "English (US)",
volume = "3",
pages = "299--305",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke

AU - Kjeldsen, Sverre E.

AU - Lyle, Paulette A.

AU - Kizer, Jorge

AU - Oparil, Suzanne

AU - Høieggen, Aud

AU - Os, Ingrid

PY - 2007

Y1 - 2007

N2 - A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.

AB - A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.

KW - Angiotensin receptor blocker

KW - Combination therapy

KW - Hydrochlorothiazide

KW - Hypertension

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=34547818674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547818674&partnerID=8YFLogxK

M3 - Article

C2 - 17703637

AN - SCOPUS:34547818674

VL - 3

SP - 299

EP - 305

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 3

ER -